OrIGINaLNI radOVI OrIGINaL arTICLEs Pathologic findings and clinical outcome in patients undergoing retroperitoneal lymphadenectomy after multiple chemorherapy regimens for metastatic nonseminomatous testicular tumors
Gj B, Rj M. Testicular germ cell cancer. N Engl j Med. 1997;242–53.
2.
Kondagunta G, Bacik. Combination of paclitaxel, ifosfamide and cisplatin is and effective secondline chemotherapy for patients with relapsed testicular germ cell tumors. Clin Oncol. 2006;6549–55.
3.
Mccaffrey Ja, Masumdar M, Df B. Ifosfamide-and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. Clin Oncol. 1997;2559–63.
4.
Motzer Rj, Masumdar M. sequential dose -intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. Clin Oncol. 2000;1173–80.
5.
Fox E, Td W, Sd W. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissection. Clin Oncol. 1993;1294–9.
6.
Hendry W, Dp N. Metastatic nonseminomatous germ cell tumors of the testis: results of effective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;1668–76.
7.
Rick O, Bokemeyer C. Weinknecht s. residual tumor resection after high-dose chemotherapy in patients with relapsed or refractory germ cell cancer. Clin Oncol. 2004;3713–9.
8.
International Germ Cell Concensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. Clin Oncol. 1997;594–603.
9.
Donohue Jp, Leivovitch I, Rs F. Integration of surgery and systemic therapy: results and principles of integration. sem in. Urol Oncol. 1998;65–71.
10.
The role of surgery in advanced testicular cancer. Cancer. 1984;(11):2716–21.
11.
Eggener Se C, Bs. Loeh s. Pathologic and clinical outcomes of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy for metastatic testicular germ cell tumors. Cancer. 2007;528–35.
12.
Fossa Sd. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. Clin Oncol. 1998;239–74.
13.
Cj L, Samuels M, De T. The growing teratoma syndrome. Cancer. 1982;1629–35.
14.
Motzer, Pineto V. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. Urol. 1998;133–8.
15.
Long-term outcome after postchemotherapy retroperitoneal lymphadenectomy in patients with residual teratoma. Eur Urol. :596.
16.
The impact of residual extra-retroperitoneal masses in patients with advanced nonseminomatous testicular tumors. Eur Urol. 2009;553.
17.
Late relapses of germ cell testicular tumours: a population based experience over 23 years. Eur Urol Meet. 2007;(5):38.
18.
Late relapses of germ cell tumors following cisplatin-based chemotherapy. Eur Urol Meet. 2007;(7):138.
19.
Beck Sd, Patel M. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors. Urol. 2004;168–71.
20.
Br M, Es B. dlonohue jP. surgical salvage of chemorefractory germ cell tumors. j Clin Oncol. 1993;324–9.
21.
Tel.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
